<DOC>
	<DOCNO>NCT01725672</DOCNO>
	<brief_summary>This open-label , randomize , single dose , four-way crossover , multi-stage study enrol 20 healthy adult male female subject per part . This study consist two separate part ( Part A B ) part comprise four treatment period . Each subject participate four treatment period per part ; Subjects may enrol Parts A B . This study conduct compare pharmacokinetics ( PK ) two extended release fix dose combination ( FDC ) oral formulation metformin glimepiride two dos , 500mg/1mg 1000mg/2mg , FDC formulation administer orally single dose compare commercially available formulation metformin extend release ( XR ) ( GLUCOPHAGE ™ Sustained Release [ SR ] ) glimepiride immediate release ( IR ) ( AMARYL ™ ) . Part A study evaluate bioavailability formulation comprise film coat tablet contain release control polymer ; Part B evaluate bioavailability formulation comprise tablet coat release control polymer . In part 4 treatment period . During period , subject randomize sequentially receive single dose reference treatment 500 mg metformin XR / 1 mg glimepiride IR ; reference treatment 1000 mg metformin XR / 2 mg glimepiride IR ; FDC tablet contain 500 mg metformin XR 1 mg glimepiride XR ; FDC tablet contain 1000 mg metformin XR 2 mg glimepiride XR.Serial PK sample 36 hour safety assessment perform . Each period separate washout period least 5 day follow-up visit occur 14 day last dose study drug .</brief_summary>
	<brief_title>Crossover Study Evaluate Comparative Bioavailability Two Fixed Dose Combination Tablet Formulations Extended Release Metformin Extended Release Glimepiride Health Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male female subject 18 65 year age inclusive body weight &gt; = 50 kg body mass index ( BMI ) within range 19 32 kilogram/meter square Alanine aminotransferase ( ALT ) alkaline phosphatase bilirubin &lt; or=1.5x upper limit normal ( ULN ) . Normal ECG measurement . Average QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 millisecond QTcF &lt; 480 msec subject Bundle Branch Block base average three electrocardiogram ( ECGs ) obtain brief recording period . Female subject nonchild bear potential . Females child bear potential eligible enter pregnant willing use protocolspecified method contraception prevent pregnancy 14 day postlast dose metformin/glimepiride . Capable give write informed consent The subject positive : drug/alcohol screen , Hepatitis , HIV screen Abuse alcohol Current chronic history liver disease , know hepatic biliary abnormality Exposure four new investigational chemical entity within 12 month prior first dose day Participated clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Donation 500 mL blood within 56 day period Pregnant lactating female Unwillingness inability follow procedure outline protocol Subject mentally legally incapacitate Subject positive urinary cotinine level indicative use tobacco nicotinecontaining product within 6 month prior screen . Unable refrain consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose Subjects asthma positive carbon monoxide ( CO ) admission Unit Unable refrain use prescription nonprescription drug within 7 day prior first dose study medication , unless approve Investigator GSK Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>glimepiride</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>metformin</keyword>
</DOC>